



Attorney Docket # 5422-2

IFW
Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Yi-Chao LEE et al.

Serial No.: 10/801,292

Filed: March 15, 2004

For: Methods for Identification, Assessment,
Prevention, and Therapy of Cancer

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on
November 18, 2004
(Date of Deposit)

Kent H. Cheng
Name of applicant, assignee or Registered Representative

Kent H. Cheng
Signature

November 18, 2004
Date of Signature

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

SIR:

Responsive to the Notice to Comply with Requirement for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated September 21, 2004, Applicants submit herewith a sequence listing for the nucleotide sequence and/or amino acid sequence disclosed in the above-identified patent application. Also enclosed is an Amendment in response to Notice under 37 CFR §§1.821-825 and a Statement to Support Filing and Submission in accordance with 37 C.F.R. §§1.821-1.825.

REMARKS

A copy of the sequence listing in computer readable form is also enclosed. The content of enclosed paper and computer readable copies of the sequence listing are the same, and the submission contains no new matter.

In the event that any additional fees or charges are deemed necessary in connection with the application at the present time, the same may be charged to our Patent and Trademark Office Deposit Account No. 03-2412.

Respectfully submitted,
COHEN, PONTANI, LIEBERMAN & PAVANE

By: Kent H. Cheng
Kent H. Cheng
Reg. No. 33,849
551 Fifth Avenue
New York, New York 10176
(212) 687-2770

Dated: 18 November 2004



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/801,292	03/15/2004	Yi-Chao Lee	5422-2

27799
 COHEN, PONTANI, LIEBERMAN & PAVANE
 551 FIFTH AVENUE
 SUITE 1210
 NEW YORK, NY 10176

CONFIRMATION NO. 3057
FORMALITIES LETTER



OC000000013858139

Date Mailed: 09/21/2004

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
 DISCLOSURES**

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts

Commissioner for Patents
 P.O. Box 1450

COHEN, PONTANI, LIEBERMAN & PAVANE

SFP 23 2004

CONFIRMATION

Alexandria VA 22313-1450


*A copy of this notice **MUST** be returned with the reply.*

Aljan

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



Attorney Docket # 5422-2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Yi-Chao LEE et al.

Serial No.: 10/801,292

Filed: March 15, 2004

For: Methods for Identification, Assessment,
Prevention, and Therapy of Cancer

Examiner:

Group Art:

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

November 18, 2004

(Date of Deposit)

Kent H. Cheng

Name of applicant, assignee or Registered Representative

Kent H. Cheng

Signature

November 18, 2004

Date of Signature

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Amendment in Response to Notice Under 37 CFR §§1.821-825

SIR:

Responsive to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed September 21, 2004, please amend the application as indicated on page 2.

Amendments to the Specification begin on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.